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Abstract
Background: Prevalence estimates for insomnia range from 10 to 50% in the adult general
population. Sleep disturbances cause great impairment in quality of life, which might even rival or
exceed the impairment in other chronic medical disorders. The economic implications and use of
health-care services related to chronic insomnia represent a clinical concern as well as a
pronounced public health problem. Hypnotics are frequently prescribed for insomnia, but alcohol
and over-the-counter sleep aids seem to be more widely used by insomniacs than prescription
medications. Despite the complex relationship between insomnia and physical and mental health
factors, the condition appears to be underrecognized and undertreated by health care providers,
probably due to the generally limited knowledge of the causes and natural development of
insomnia.
Methods/Design: The Tromsø Study is an ongoing population-based cohort study with five
previous health studies undertaken between 1974 and 2001. This protocol outlines a planned study
within the sixth Tromsø Study (Tromsø VI), aiming at; 1) describing sleep patterns in a community-
based sample representative of the general population of northern Norway, and 2) examining
outcome variables of sleep disturbances against possible explanatory and confounding variables,
both within a cross-sectional approach, as well as retrospectively in a longitudinal study – exploring
sleep patterns in subjects who have attended two or more of the previous Tromsø studies between
1974 and 2009. First, we plan to perform a simple screening in order to identify those participants
with probable sleep disturbances, and secondly to investigate these sleep disturbances further,
using an extensive sleep-questionnaire. We will also collect biological explanatory variables, i.e.
blood samples, weight, height and blood pressure. We plan to merge data on an individual level
from the Tromsø VI Study with data from the Norwegian Prescription Database (NorPD), which
is a national registry including data for all prescription drugs issued at Norwegian pharmacies.
Participants with sleep disturbances will be compared with pair-matched controls without sleep
disturbances.
Discussion: Despite ongoing research, many challenges remain in the characterization of sleep
disturbances and its correlates. Future mapping of the biological dimensions, natural history, as well
as the behavioral and drug-related aspects of sleep disturbances in a representative population
samples is clearly needed.
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Insomnia is the subjective complaint of insufficient sleep
quantity or quality leading to impaired daytime function-
ing, usually linked to difficulties in falling asleep, trouble
staying asleep, waking up too early in the morning or non-
restorative sleep [1]. The real prevalence of insomnia is
not known, but prevalence estimates, which in part are
influenced by diagnostic definitions, range from 10 to
50% in the adult population [2].
Insomnia is classified as transient (no more than a few
nights), acute (less than 3 to 4 weeks), and chronic (more
than 3 to 4 weeks). Transient or acute insomnia usually
occurs in people with no history of sleep disturbances and
is often related to an identifiable cause [3]. Chronic
insomnia is further divided into primary and secondary
conditions, depending on the cause [4]. When the com-
plaint of insomnia is not caused by other medical, psychi-
atric or medication-related disorders, it is considered to be
primary in nature [4]. It is estimated that primary insom-
nia accounts for approximately 25% of all chronic insom-
nia [5]. Recently, The American National Institutes of
Health State-of-the-Science Conference suggested that
insomnia should be conceptualized as a disorder in and
of itself, which is or is not comorbid with other disorders
– rather than drawing conclusions about insomnia's pri-
mary or secondary status [6].
Excessive daytime sleepiness is a key symptom of any type
of disturbed sleep. Sleepiness is defined by recurrent epi-
sodes of drowsiness or involuntary dozing that arise
mainly in sedentary situations. Sleepiness should not be
confused with fatigue or tiredness. Although subjective
reports of sleepiness are common in people with insom-
nia, many studies report normal or even heightened levels
of daytime alertness among insomniacs, e.g. as measured
with the Epworth sleepiness scale (ESS) [7,8] or the Mul-
tiple Sleep Latency Test (MSLT) [9-12]. On the other
hand, insomnia patients usually experience more fatigue
than patients with other sleep disturbances, such as
obstructive sleep apnea, narcolepsy or periodic limb
movements during sleep [7,13].
Table 1: Factors related to chronic insomnia
Specific sleep disturbances:
• Circadian rhythm disorders:
 Advanced sleep-phase syndrome
 Delayed sleep-phase syndrome
• Sleep apnea (obstructive, central, or mixed)
• Restless leg syndrome
• Periodic limb movement disorders (nocturnal myoclonus)
• Parasomnias, i.e. REM-sleep-behavior-disorder
Physical illness:
• Pain: arthritis, musculoskeletal pain, other painful conditions
• Cardiovascular: heart failure, nocturnal breathlessness, nocturnal angina
• Pulmonary: chronic obstructive pulmonary disease, allergic rhinitis (nasal obstruction)
• Gastrointestinal: gastroesophageal reflux disease, peptic ulcer disease, constipation, diarrhea, pruritus ani
• Urinary: nocturia, incomplete bladder emptying, incontinence
• Central nervous system: stroke, Parkinson disease, Alzheimer disease, seizure disorder
• Psychiatric illness: anxiety, depression, psychosis, dementia, delirium
• Pruritus
• Menopause (hot flushes)
Behavioral: daytime nap, early retirement to bed, use of bed for other activities (eg, reading and watching television), heavy meals, lack of exercise, 
and sedentary lifestyle
Environmental: noise, light and other disturbances, extreme temperatures, uncomfortable bedding, and lack of exposure to sunlight
Medications:
• Central nervous system stimulants: sympathomimetics, caffeine, nicotine, amphetamines, ephedrine, phenytoin
• Antidepressants: bupropion, selective serotonin reuptake inhibitors, venlafaxine
• Anti-Parkinsonian agents: levodopa
• Bronchodilators: theophylline
• Cardiovascular: B-blockers, diuretics
• Histamines, H2 blockers: cimetidine
• Anticholinergics
• Corticosteroids
• Alcohol
• Herbal remedies
• Stimulant laxative
REM = rapid eye movement.Page 2 of 9
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nia (Table 1). Precipitants of acute insomnia may include
acute medical illness, hospitalization, changes in the
sleeping environment, medications, jet lag, and acute or
recurring psychosocial stressors [3]. Chronic insomnia is
often linked to or associated with various underlying
medical, behavioral, and environmental conditions
[3,14,15], and various medications [14-16]. Especially
mental disorders and discomfort are frequently reported
by insomniacs. In a survey of 811 respondents, 40% of
those with insomnia (compared with 16% of those with-
out), met the criteria for one or more psychiatric diag-
noses [17]. Although it is difficult to discern whether a
psychiatric disorder precipitates insomnia or whether
insomnia makes an individual vulnerable to the emer-
gence of a psychiatric disorder, investigations indicate an
increased risk for new onset of depression, anxiety disor-
ders, and substance abuse in people with persistent
insomnia [18]. Additionally, insomnia may be precipi-
tated by factors like stress and perpetuated by behavioral
factors, or unstable sleep schedules. Shift work or other
lifestyle factors that disrupt circadian rhythm increase the
risk of sleep disturbances [19].
An association between elevated body mass index (BMI)
and short sleep duration has been demonstrated in recent
years [20]. A possible causality between short sleep dura-
tion and the development of diabetes mellitus (DM) has
also been explored. Gottlieb et al. [21] reported that short
sleep duration is associated with DM and impaired glu-
cose tolerance (IGT) in community-dwelling middle-aged
and older adults. This association persisted after adjust-
ment for known DM risk factors. Sleep restriction to four
hours of sleep per night increased blood pressure,
decreased parasympathetic tone, increased evening corti-
sol and insulin levels, and promoted increased appetite,
possibly through the elevation of ghrelin, a pro-appetitive
hormone, and decrease in levels of leptin [22-24]. The
correlation between short sleep duration with DM and
IGT may partly explain the association between short
sleep duration and coronary heart disease [25] and all
over mortality [26-28].
Sleep patterns change throughout life. It seems as if ageing
makes it more difficult to stay asleep at night and to stay
awake during the day [29]. Total sleep time during the 24-
hour period appears to decline with advancing age,
accompanied by a redistribution of sleep – with decreased
nocturnal sleep and increased daytime napping [29]. Pro-
gressive physical inactivity, dissatisfaction with social life,
and presence of physical and mental problems may be the
most predictive factors of insomnia in the elderly [30].
Opposed to healthy elderly, sleep duration during the 24-
h day in demented nursing home patients seems to
increase according to the degree of dementia [31]. Some
researchers claim that ageing probably is the single most
important factor that determines human sleep – more so
than gender and even most physical and mental illnesses
[32]. However, challenging findings of no reduction of
nocturnal sleep with age in healthy elderly have also been
presented, suggesting that insomnia in the elderly is not
related to ageing itself [33-35].
It is known that hypnotics are frequently prescribed for
insomnia [36]. However, alcohol and over-the-counter
(OTC) medications seem to be more widely used by
insomniacs than prescription medications [37], perhaps
due to the fact that most insomniacs do not discuss their
sleep problems with their doctor [38]. In a general popu-
lation sample of 2.181 adults aged 18 to 45 years, John-
son et al. [37] found that 25.9% had used any substance
as a sleep aid in the past 12 months. Approximately 18%
reported using medications (57% of these being OTC-
drugs), and 13% reported using alcohol to fall asleep. The
choice of substance used as a sleep aid seems to be
affected by sociodemographic characteristics: Most
chronic benzodiazepine users tend to be elderly [39], and
more men than women use alcohol to induce sleep. Roks-
tad et al. [40] examined the prescribing patterns among
general practitioners (GPs) in a Norwegian county in rela-
tion to the patients' age, gender and the diagnosis for pre-
scribing, and found that insomnia was among the most
commonly recorded diagnosis for prescribing. Most drugs
have not been sufficiently studied to determine their pri-
mary effects on sleep and waking behavior [41]. Even
when the effects of a drug are known, the medication may
act differently in normal individuals and individuals who
are ill [41].
The economic implications and use of health-care services
related to chronic insomnia represent a major problem.
Costs related to chronic insomnia do not only include the
direct costs of health-care, but also the indirect costs
related to absence from work, diminished productivity,
accidents, and other health problems that are, at least in
part, secondary to insomnia [42-44].
Compared to other sleep disturbances, such as narcolepsy
and sleep apnea, the understanding of the basic patho-
physiology of insomnia has lagged behind [45]. This dis-
crepancy probably stems from the heterogeneous nature
of insomnia. On one hand, insomnia may be a primary
condition with a pathophysiology, like a general state of
hyperarousal – which includes changes like increased lev-
els of catecholamines [46], increased basal metabolic rate
[47], increased body temperature [48], altered heart rate
[47], increased level of central nervous system (CNS) met-
abolic rate [49], and elevated electroencephalograph
activity [50,51]. On the other hand, insomnia may be aPage 3 of 9
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disorders.
Further knowledge of the impact of latitude, daytime illu-
mination and season, on the prevalence of insomnia is
needed [52]. The term "midwinter insomnia" has been
applied for the seasonal type of insomnia observed in arc-
tic areas during the dark periods of the year [53], but the
possible consequences of annual variations in environ-
mental light on sleep are still not settled [52,54], and
make arctic sleep studies especially relevant.
Semantic as well as definition confusions are present in
many epidemiological sleep studies. This situation proba-
bly rises from the fact that no single and clear definition
exists of insomnia and how to assess it [33]. As a result,
very different and non-comparable sleep assessment tools
exist – making it is almost impossible to compare and
summarize studies.
Our knowledge of insomnia is still limited, especially
regarding its evolution and consequences in the general
population [33]. Future sleep research is in need of vali-
dated measurements of sleep complaints, in order to pro-
vide common metrics for describing insomnia and
insomniacs in epidemiological studies.
Below, we describe the protocol for a longitudinally, ret-
rospective cohort survey and a cross-sectional study in a
large representative adult community sample in northern
Norway (The Tromsø Study). Using validated sleep assess-
ment tools, our aim is to describe and analyze sleep dis-
turbances, with their correlating and predisposing factors.
Aims and objectives
The Tromsø Study is a large ongoing population-based
cohort study with five previous health studies undertaken
between 1974 and 2001 (Table 2). This protocol outlines
a planned study in the sixth Tromsø Study (Tromsø VI),
which will be carried out in 2008–2009.
The Tromsø Study is well suited for sleep studies in the
general population, with its unique availability of multi-
ple objective biological measures, as well as current med-
ication use, physical and psychosocial functioning –
which will allow research on independent correlates of
sleep disturbances.
This protocol describes two main aims:
1) To present descriptive sleep data of a community-based
sample representative of the general population of north-
ern Norway.
2) To examine sleep outcome variables against potential
explanatory variables examine, both within a cross-sec-
tional approach, as well as retrospectively in a longitudi-
nal study exploring development of sleep characteristic in
subjects having attended two or more of the Tromsø stud-
ies between 1974 and 2009.
We plan to merge data on an individual level from the
Tromsø VI Study with data from the Norwegian Prescrip-
tion Database (NorPD), which is a national registry
including data for all prescription drugs issued at Norwe-
gian pharmacies since 2004 [55]. This will enable research
on drug-related sleep complaints.
In addition to the two main aims outlined in this proto-
col, we are planning a follow-up controlled cohort-study,
which will include subjects with sleep complaints
recruited in Tromsø VI. This prospective study will aim to
investigate possible causal factors of insomnia, and will
be described in detail in a later protocol.
Methods
Setting
The current study will be performed in a non-institution-
alized general population in northern Norway, aged 20 to
90 years. Samples will be drawn in a two-stage procedure,
described below.
In the first stage, data from all eligible participants in the
Tromsø VI Study will be assessed, in order to describe
sleep disturbances and their associated risk factors. In the
initial survey, self-reported sleep disturbances will be
Table 2: Participation in five previous Tromsø Studies, 1974 to 2001
No. invited No. attending Attendance (%)
Study Year Year of birth Men Women Men Women Men Women
Tromsø I 1974 1927–1956 8 867 6 595 83
Tromsø II 1979–1980 1925–19591 11 481 9 959 8 477 8 144 73.8 81.8
Tromsø III 1986–1987 1925–19661 14 539 12 877 10 413 10 189 71.6 79.1
Tromsø IV 1994–1995 <1970 18 480 19 078 12 865 14 293 69.6 74.9
Tromsø V 2001 <19722 4 636 5 717 3 511 4 619 75.7 80.8
1From 1930 onward for women. 2Full birth cohorts were not included. See text for description.Page 4 of 9
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tion; "During the last 12 months, how often have you
experienced sleep disturbances?", answered with a four-
item response: "never", "1–3 times per month", "once a
week" or "more than once a week". In this initial screening,
the selection criterion for sleep disturbances will be "more
than once a week".
In the second stage, all participants who report sleep dis-
turbances ("more than once a week") will be invited to a sec-
ond cross-sectional survey, where sleep complaints and
daytime sleepiness will be mapped, using a sleep assess-
ment questionnaire (questionnaire 2 = Q2) described
below. A pair-matched control group (matched for age
and gender) will be recruited among the remaining partic-
ipants (those without sleep complaints).
Assuming that the prevalence of sleep complaints in the
Tromsø VI Study corresponds to previous estimates for the
general population, we expect to include 10 to 15% of the
total study population into the sleep complaint group.
In order to analyze possible seasonal effects due to the
natural annual light-dark cycle in the artic, we will exam-
ine a random half of the participants in the sleep com-
plaint group and control group with Q2 in the part of the
year with the highest levels of environmental light (May-
June), and examine the remaining participants with Q2 in
the part of the year with the lowest levels of environmen-
tal light (November-December).
Questionnaires
All participants in Tromsø VI will be asked to complete an
extensive questionnaire (Q1), including demographic
data, socioeconomic variables, subjective health percep-
tion, quality of life, current medical diagnoses and symp-
toms, use of prescription drugs and OTC-drugs, use of and
satisfaction with health services. In addition, biological
markers (i.e. blood samples, height, weight, blood pres-
sure) will be collected.
The sleep assessment questionnaire (Q2) will among
other items include the Epworth Sleepiness Scale (ESS)
and the Pittsburgh Sleep Quality Index (PSQI).
The ESS [8] is useful in measuring the frequency of day-
time sleepiness, and has been used in numerous studies
[56-60]. ESS evaluations have demonstrated significant
association between daytime sleepiness and insomnia
[59], and have allowed quantitative analysis of the effects
of pharmacologic and non-pharmacologic therapies on
daytime sleepiness in poor sleepers [56,60]. Subjects are
instructed to rate the chance of dozing off or falling asleep
in eight different "real-life" circumstances. Grading of
each item ranges from 0 to 3 and the maximum total score
reaches 24. Values over 10 are regarded as indicative of
excessive daytime sleepiness [8,61]
The PSQI is a self-rated questionnaire assessing sleep
quality and disturbances lasting for more than 1 month
[62]. This subjective measure has been validated against
polysomnography (PSG) [62-64], which is considered the
gold-standard for measuring sleep disturbances [65]. The
PSQI is now one of the most commonly used assessments
for the evaluation of insomnia severity in sleep research
[65,66], and its validity has been demonstrated for
patients with mental disorders [62,67], for patients with
different somatic diseases [68], and for healthy elderly
subjects [63].
Sleep assessment tools, such as ESS and PSQI, are usually
treated as binary variables in large population-based stud-
ies, according to their cut-off values for "normal" vs.
"insomnia". For clinicians, however, a more accurate
grading of insomnia is usually needed and the scales are
used as continuous variables in order to grade insomnia
into e.g. "mild", "moderate" or "severe".
In addition to the PSQI and ESS, Q2 will also address
presence of restless legs, nightmares, shift-work and self-
reported strategies for coping with insomnia.
Population
The Norwegian city of Tromsø is situated 70° north of the
equator and north of the Arctic Circle. It is the largest city
in northern Norway, with approximately 60.000 inhabit-
ants. The aims of the repeated Tromsø studies (Table 2)
are to investigate determinants for chronic diseases and to
identify potentially modifiable determinants that may
contribute to the development of preventive strategies.
In 2001, the size of the study population was 8.130 per-
sons, which was considerably less than most previous
Tromsø studies. This was a result of a steered invitation
policy to those individuals attending two sub-populations
in the 1994/1995 Study.
The size of the population to be invited in the forthcom-
ing Tromsø VI Study is still not established, but is
expected to be about 12.000 in the age from 20 to 90
years.
Outcome measures
Outcome measures in the first part of this study will be the
prevalence of sleep disturbances as reported in the initial
questionnaire (Q1) containing a four-item response
option, where sleep disturbance is defined as the average
occurrence of sleep problems "more than once a week".Page 5 of 9
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further mapped by a sleep questionnaire (Q2), sent by
mail to subjects in the sleep complaint group and in an
approximately equal-sized control group. Recruitment,
pair matching, questionnaire logistics (including remind-
ers) will be handled by the Tromsø Study's central body,
situated at the University of Tromsø. Outcome measures
are summarized in Table 3.
Statistics
Below, we describe the most probable statistical
approaches in the evaluation of associations between self-
reported sleep disturbances and exposures. However, in
the course of analyses, and with further knowledge of the
actual data set, the statistical approach may be supple-
mented and/or modified. SPSS version 14.0 will be used
for statistical analyses. STATA 10 is used for sample size
and power calculations.
Age adjustments in groups of subjects with sleep com-
plaints will be performed by the direct method with the
Norwegian population serving as standard population.
We plan to carry out series of tabular analyses, tabulating
our outcome variables against potential explanatory and
confounding variables. These tabulations will guide fur-
ther analyses. A matched regression analysis will be done
using conditional logistic regression in SPSS. For each
model we will compare the results of the univariate anal-
yses to those of multivariate analyses. We aim to construct
credible parsimonious explanatory models, which will be
critiqued using residual analysis, and the Hosmer-Leme-
show goodness of fit test.
Relevant variables that reach significance in bivariate ana-
lyzes, will be entered into a multiple logistic regression
Table 3: Sleep outcome variables, potential explanatory variables and their pre-specified associations in the Tromsø Study
Sleep outcome variables against potential explanatory variables Pre-specified associations References
Initial screening of all eligible participants in the Tromsø Study:
• Prevalence of sleep disturbances reported in the initial questionnaire 
(Questionnaire 1) containing a four-item response option, where sleep 
disturbance is defined as the average occurrence of sleep problems 
"more than once a week".
10 to 50% in the adult population. [2, 76]
• Sleep disturbances and their possible relationships, including 
demographic variables, health-related variables, and lifestyle and 
socioeconomic variables, and biological markers.
Increased risk for impairments in health, decreased 
quality of life and increased healthcare utilization.
[19, 65, 77-80]
Further mapping with validated sleep assessment questionnaires among 
subjects with sleep complaints selected in the initial screening and their 
control group:
• Sleep outcome variables related to the use (dose and frequency) of 
specific prescription drugs, derived from the Norwegian Prescription 
Database (NorPD).
Frequent use of hypnotics and over-the-counter 
(OTC) medications.
[36, 37]
• Sleep outcome variables related to socioeconomic variables. Insomnia related to unemployment and 
socioeconomic deprivation, more common in 
women, elderly and individuals living alone.
[81, 82]
• Sleep outcome variables and excessive daytime sleepiness related to 
objective medical diagnosis, such as diabetes and coronary disease.
A possible link between short sleep, diabetes 
mellitus, coronary heart disease and all over 
mortality.
[21, 25-28]
• Sleep outcome variables related to the diagnosis of restless legs. Relation between symptoms of restless legs and 
insomnia
[15]
• Sleep outcome variables related to self-reported complaints of 
musculoskeletal symptoms.
Relation between symptoms of musculoskeletal 
symptoms and insomnia
[83]
• Sleep outcome variables related to self-reported psychiatric symptoms Elevated risk of depression and anxiety disorders in 
people with persistent insomnia
[58, 77, 84-86]
• Sleep outcome variables related to self-reported frequency of 
nightmares.
Possible association between nightmares and being 
a woman, feeling depressed after a poor night's 
sleep, and complaining of a long sleep latency.
[87]
• Sleep outcome variables related to excessive daytime sleepiness and 
reported actual sleep length.
Daytime sleepiness inversely related to hours of 
sleep and positively related to the ease of falling 
asleep at night, especially among young adults.
[88, 89]
• Sleep outcome variables and excessive daytime sleepiness related to 
subjective perceptions of pain
Chronic pain populations are more likely to 
experience chronic insomnia, sleep maintenance 
problems, and/or nonrestorative sleep.
[17, 35, 90]
• Sleep outcome variables and excessive daytime sleepiness related to 
doctor-seeking behaviour.
Although insomnia is related to more consultations 
with GPs, many individuals hesitate to consult their 
doctor about insomnia
[72, 82]Page 6 of 9
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variables.
Some of the variables might have missing values. One
possible way to deal with missing values is by multiple
imputation. To include most of the observations in the
model, the missing values may be included after an impu-
tation procedure in SPSS, where the missing value is
replaced by the mean of the non-missing values for that
variable.
From the first initial screening to the subsequent mapping
with the extensive sleep-questionnaire, it may happen
that some subjects defined as "cases" reach normal values
and vise versa. These subjects and their matched control/
case will be excluded from later analyses.
We have calculated sample sizes for three main variables
in this study: PSQI, EES and BMI (p value for significance
= 0.05 (two-sided) and power = 90 %). Ideally, the size of
the effect to be detected should be base on clinical judg-
ments, but this is not always straightforward. The effect
should be large enough to be clinically important but not
so large that it is implausible. We have based our esti-
mates of clinical effects on previous studies of insomniacs
compared to healthy controls for PSQI [69], ESS[70]and
BMI [20]. We have calculated the standard deviations for
each variable (PSQI = 4.58, ESS = 5.9 and BMI = 5.7), and
decided that clinically relevant differences for these varia-
bles are PSQI > 2, ESS > 2 and BMI > 1. The necessary sam-
ple sizes (number of pairs) to detect significant differences
between cases and controls are; PSQI = 56 pairs, ESS = 92
pairs and BMI = 342 pairs. Thus, for the three variables
above, the planned study seems to be large enough to
detect differences between groups.
Recruitment and randomization
Recruitment of participants to the Tromsø VI Study will be
carried out of the study's central body, situated at the
Medical Faculty, University of Tromsø. The present plan is
to invite the following subgroups in the county of
Tromsø:
• A 10% random sample of all inhabitants aged 20 to 39
years.
• All inhabitants aged 40 to 42 years.
• A 10% random sample of all inhabitants aged 43 to 59
years.
• All inhabitants aged 60 to 79 years.
• All inhabitants older than 80 years who have attended at
least one of the previous Tromsø studies.
This will comprise a total population of approximately
15.000 persons. An attendance of 80% would imply a
study population of approximately 12.000 persons.
Ethics and data security
Before the recruitment in the current study, all partici-
pants will be informed about the objectives for the study,
including that their participation is voluntarily and that
they are granted full anonymity. A written informed con-
sent will be obtained from all participants. The study will
be presented for The Regional Committee for Research
Ethics and for The Norwegian Social Science Data Services
(NSD).
Discussion
Sleep disturbances cause great impairment in quality of
life [71-73]. The degree of impairment correlates with
severity of sleep disturbance and may even rival or exceed
the impairment in other chronic medical disorders, like
DM, arthritis and heart disease [74]. A wide range of
health aspects may be compromised, such as occupational
adjustment, physical and social functioning and mental
health. Individuals with serious sleep disturbances report
diminished energy, concentration, and memory distur-
bance [18,74,75].
Despite ongoing research, many challenges remain in the
characterization of sleep disturbances and its correlates
[65]. Retrospective epidemiologic studies have not fully
defined sleep disturbances' natural history and pathology
[65]. Population-based surveys often yield observational
and/or subjective patient-reported data, and there is a
remaining need to include sufficient analysis of objective
assessments, confounding and/or risk factors and the
presence/absence of co-morbidities [65]. Future mapping
of the biological dimensions, natural history, as well as
the behavioral and drug-related aspects of sleep distur-
bances in representative population samples is clearly
needed.
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